







- 
- 
- [Home](#)
- [Company](#)
 - [Overview](#)
 - [Management](#)
 - [Board of Directors](#)
 - [Partners](#)
 - [Scientific and Medical Advisors](#)
- [Technology](#)
 - [Prima Bionic Vision System](#)
- [Patients](#)
 - [Overview](#)
 - [Blindness](#)
 - [Age-related macular degeneration \(AMD\)](#)
 - [Useful Links](#)
- [Clinical Trial](#)
 - [PRIMAvera Pivotal Study](#)
 - [Dry AMD PRIMA](#)
- [Investors](#)
 - [Overview](#)
 - [In the News](#)
 - [Press Releases](#)
 - [Conferences](#)
 - [Financial Reports & Documents](#)
 - [Analyst Coverage](#)
 - [Other Regulated Information](#)
 - [Shareholder's General Meeting](#)
 - [Stock Information](#)
 - [Financial Calendar](#)
 - [Contact Us](#)
- [Media](#)
 - [Events](#)
 - [Press Kit](#)
- [Professionals](#)
- [Contact Us](#)
 - [Contact Us](#)
 - [Job Opportunities](#)

- [UK](#)
 - [FR](#)
 - [Home](#)
 - [Company](#)
 - [Overview](#)
 - [Management](#)
 - [Board of Directors](#)
 - [Partners](#)
 - [Scientific and Medical Advisors](#)
 - [Technology](#)
 - [Prima Bionic Vision System](#)
 - [Patients](#)
 - [Overview](#)
 - [Blindness](#)
 - [Age-related macular degeneration \(AMD\)](#)
 - [Useful Links](#)
 - [Clinical Trial](#)
 - [PRIMAvera Pivotal Study](#)
 - [Dry AMD PRIMA](#)
 - [Investors](#)
 - [Overview](#)
 - [In the News](#)
 - [Press Releases](#)
 - [Conferences](#)
 - [Financial Reports & Documents](#)
 - [Analyst Coverage](#)
 - [Other Regulated Information](#)
 - [Shareholder's General Meeting](#)
 - [Stock Information](#)
 - [Financial Calendar](#)
 - [Contact Us](#)
 - [Media](#)
 - [Events](#)
 - [Press Kit](#)
 - [Professionals](#)
 - [Contact Us](#)
 - [Contact Us](#)
 - [Job Opportunities](#)
- [Home](#)[Board of Directors, Management](#)[Lloyd Diamond](#)[CEO](#)

[Previous](#) [Next](#)

Lloyd Diamond

CEO



Lloyd Diamond, a US citizen, is a seasoned medtech executive and CEO with 25 years of disruptive technology commercialization experience in the life science industry. He most recently served as the CEO of Precise Light Surgical, a commercially ready medical device company in Silicon Valley. Prior to that, he was the CEO of Bonesupport AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US which led to a successful IPO on the NASDAQ OMX in Stockholm. Lloyd has first-hand experience in the ophthalmology segment as he was responsible for managing Lumenis' global surgical and vision franchises. He has commercialized many other disruptive technology platforms including at Kyphon and Laserscope. Lloyd received a dual degree in Biochemistry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at Arizona State University.

Partagez ce contenu, choisissez votre plateforme !

[Facebook](#)[Twitter](#)[Reddit](#)[LinkedIn](#)[WhatsApp](#)[Tumblr](#)[Pinterest](#)[Vk](#)[Xing](#)[Email](#)

PIXIUM VISION is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy

[Privacy Policy](#)

[Legal Terms](#)

PIXIUM VISION

74 rue du Faubourg Saint-Antoine

75012 Paris, France

Phone: +33 1 76 21 47 68

Fax: +33 1 43 42 05 26

Web: www.pixium-vision.com

